Different loss of material in recurrent chromosome 20 interstitial deletions in Shwachman-Diamond syndrome and in myeloid neoplasms

Molecular Cytogenetics

Volumn 6, Issue 1, 2013, Pages

  Valli, Roberto ^a   Pressato, Barbara ^a   Marletta, Cristina ^a   Mare, Lydia ^a   Montalbano, Giuseppe ^a   Curto, Francesco Lo ^a   Pasquali, Francesco ^a   Maserati, Emanuela ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

del(20)(q); Myeloid neoplams; Shwachman Diamond syndrome

Indexed keywords

EID: 84889968786     PISSN: None     EISSN: 17558166     Source Type: Journal    
DOI: 10.1186/1755-8166-6-56     Document Type: Article

References (34)

1. Shwachman-Diamond syndrome. Dror Y, Pediatr Blood Cancer 2005 45 892 901 10.1002/pbc.20478 16047374 (Pubitemid 41552156)
2. del(20q) in myeloid malignancies. Bilhou-Nabera C, Atlas Genet Cytogenet Oncol Haematol 2000 http://AtlasGeneticsOncology.org/Anomalies/del20qID1040.html
3. Chromosomal aberrations in congenital bone marrow failure disorders-an early indicator for leukemogenesis? Göhring G, Karow A, Steinemann D, Wilkens L, Lichter P, Zeidler C, Niemeyer C, Welte K, Schlegelberger B, Ann Hematol 2007 86 733 739 10.1007/s00277-007-0337-z 17653548 (Pubitemid 47337936)
4. A clinical algorithm predicts hematological complications in Shwachman-Diamond syndrome? Liu JM, Expert Rev Hematol 2012 5 373 375 10.1586/ehm.12.31 22992231
5. Deletion of chromosome 20 in bone marrow of patients with Shwachman-Diamond syndrome, loss of the EIF6 gene and benign prognosis. Pressato B, Valli R, Marletta C, Mare L, Montalbano G, Lo Curto F, Pasquali F, Maserati E, Br J Haematol 2012 157 503 505 10.1111/j.1365-2141.2012.09033.x 22295858
6. Refinement of the smallest commonly deleted segment of chromosome 20 in malignant myeloid diseases and development of a PAC-based physical and transcription map. Wang PW, Eisenbart JD, Espinosa R III, Davis EM, Larson RA, Le Beau MM, Genomics 2000 67 28 39 10.1006/geno.2000.6215 10945467 (Pubitemid 30471118)
7. Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. Bench AJ, Nacheva EP, Hood TL, Holden JL, French L, Swanton S, Champion KM, Li J, Whittaker P, Stavrides G, Hunt AR, Huntly BJ, Campbell LJ, Bentley DR, Deloukas P, Green AR, together with the UK Cancer Cytogenetics Group (UKCCG), Oncogene 2000 19 3902 3913 10.1038/sj.onc.1203728 10952764 (Pubitemid 30658981)
8. Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis. Huh J, Tiu RV, Gondek LP, O'Keefe CL, Jasek M, Makishima H, Jankowska AM, Jiang Y, Verma A, Theil KS, McDevitt MA, Maciejewski JP, Genes Chromosomes Cancer 2010 49 390 399 20095039
9. Microarray CGH analyses of chromosomal 20q deletions in patients with hematopoietic malignancies. Okada M, Suto Y, Hirai M, Shiseki M, Usami A, Okajima K, Teramura M, Mori N, Motoji T, Cancer Genet 2012 205 18 24 10.1016/j.cancergen.2011.12.002 22429594
10. Shwachman syndrome as mutator phenotype responsible for myeloid dysplasia/neoplasia through karyotype instability and chromosome 7 and 20 anomalies. Maserati E, Minelli A, Pressato B, Valli R, Crescenzi B, Stefanelli M, Menna G, Sainati L, Poli F, Panarello C, Zecca M, Lo Curto F, Mecucci C, Danesino C, Pasquali F, Genes Chromosomes Cancer 2006 45 375 382 10.1002/gcc.20301 16382447 (Pubitemid 43346769)
11. The route to development of myelodysplastic syndrome/acute myeloid leukaemia in Shwachman-Diamond syndrome: the role of ageing, karyotype instability, and acquired chromosome anomalies. Maserati E, Pressato B, Valli R, Minelli A, Sainati L, Patitucci F, Marletta C, Mastronuzzi A, Poli F, Lo Curto F, Locatelli F, Danesino C, Pasquali F, Br J Haematol 2009 145 190 197 10.1111/j.1365-2141.2009.07611.x 19222471
12. Comparative genomic hybridization on microarray (a-CGH) in constitutional and acquired mosaicism may detect as low as 8% abnormal cells. Valli R, Marletta C, Pressato B, Montalbano G, Lo Curto F, Pasquali F, Maserati E, Mol Cytogenet 2011 4 13 10.1186/1755-8166-4-13 21554683
13. Evaluating chromosomal mosaicism by array comparative genomic hybridization in haematological malignancies: the proposal of a formula. Valli R, Maserati E, Marletta C, Pressato B, Lo Curto F, Pasquali F, Cancer Genet 2011 204 216 218 10.1016/j.cancergen.2011.02.002 21536241
14. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Gondek LP, Tiu R, O'Keefe CL, Sekeres MA, Theil KS, Maciejevski JP, Blood 2008 111 1534 1542 17954704 (Pubitemid 351213443)
15. High-resolution whole genome tiling path array CGH analysis of CD34§ssup§+§esup§ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Starczynowski DT, Vercauteren S, Telenius A, Sung S, Tohyama K, Brooks-Wilson A, Spinelli JJ, Eaves CJ, Eaves AC, Horsman DE, Lam WL, Karsan AC, Blood 2008 112 3412 3424 10.1182/blood-2007-11-122028 18663149
16. Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Heinrichs S, Kulkarmi RV, Bueso-Ramos CE, Levine RL, Loh ML, Li C, Neuberg D, Kornblau SM, Issa J-P, Gilliland DG, Garcia-Manero G, Kantarjian HM, Estey EH, Look AT, Leukemia 2009 23 1605 1613 10.1038/leu.2009.82 19387468
17. Acquired mutations in TET2 are common in myelodysplastic syndromes. Langemeijer SMC, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Stevens-Linders E, Van Hoogen P, Geurts Van Kessel A, Raymakers RAP, Kamping EJ, Verhoef GE, Verburgh E, Hagemeijer A, Vendenberghe P, De Witte T, Van der Reijden BA, Jansen JH, Nat Genet 2009 41 838 843 10.1038/ng.391 19483684
18. High-resolution oligonucleotide array comparative genomic hybridization study and methylation status of the RPS14 gene in de novo myelodysplastic syndromes. Borze I, Juvonen E, Ninomiya S, Jee KJ, Elonen E, Knuutila S, Cancer Genet Cytogenet 2010 197 166 173 10.1016/j.cancergencyto.2009.11.012 20193850
19. Assessing karyotype precision by microarray-based comparative genomic hybridization in the myelodysplastic/myeloproliferative syndromes. Slovak ML, Smith DD, Bedell V, Hsu Y-H, O'Donnell M, Forman SJ, Gaal K, McDaniel L, Schultz R, Ballif BC, Shaffer LG, Mol Cytogenet 2010 3 23 10.1186/1755-8166-3-23 21078186
20. The paradox of 20q11.21 amplification in a subset of cases of myeloid malignancy with chromosome 20 deletion. McKinnon RN, Selan C, Wall M, Campbell LJ, Genes Chromosomes Cancer 2010 49 998 1013 10.1002/gcc.20806 20645416
21. Clonal selection of 11q CN-LOH and CBL gene mutation in a serially studied patient during MDS progression to AML. Barresi V, Palumbo GA, Musso N, Consoli C, Capizzi C, Meli CR, Romano A, Di Raimondo F, Condorelli DF, Leuk Res 2010 34 1539 1542 10.1016/j.leukres.2010.07.004 20674974
22. Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia. Parkin B, Erba H, Ouillette P, Roulston D, Purkayastha A, Karp J, Talpaz M, Kujawski L, Shakhan S, Li C, Shedden K, Malek SN, Blood 2010 116 4958 4967 10.1182/blood-2010-01-266999 20729466
23. Clonal heterogeneity in childhood myelodysplastic syndromes-challenge for the detection of chromosomal imbalances by array-CGH. Praulich I, Tauscher M, Göhring G, Glaser S, Hofmann W, Feurstein S, Flotho C, Lichter P, Niemeyer CM, Schlegelberger B, Steinemann D, Genes Chromosomes Cancer 2010 49 885 900 10.1002/gcc.20797 20589934
24. A cryptic deletion in 5q31.2 provides further evidence for a minimally deleted region in myelodysplastic syndromes. McKinnon RN, Kannourakis G, Wall M, Campbell LJ, Cancer Genet 2011 204 187 194 10.1016/j.cancergen.2011.02.001 21536236
25. Evidence-based genomic diagnosis characterized chromosomal and cryptic imbalances in 30 elderly patients with myelodysplastic syndrome and acute myeloid leukemia. Bajaj R, Xu F, Xiang B, Wilcox K, DiAdamo AJ, Kumar R, Pietraszkiewicz A, Halene S, Li P, Mol Cytogenet 2011 4 3 10.1186/1755-8166-4-3 21251322
26. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Klampfl T, Harutyunyan A, Berg T, Gisslinger B, Schalling M, Bagienski K, Olcaydu D, Passamonti F, Rimu E, Pietra D, Jäger R, Pieri L, Guglielmelli P, Iacobucci I, Martinelli G, Cazzola M, Vannucchi AM, Gisslinger H, Kralovics R, Blood 2011 118 167 176 10.1182/blood-2011-01-331678 21531982
27. Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms. Rice KL, Lin X, Wolniak K, Ebert BL, Berkofsky-Fessler W, Buzzai M, Sun Y, Xi C, Elkin P, Levine R, Golub T, Gilliland DG, Crispino JD, Licht JD, Zhang W, Blood Cancer J 2011 1 40 10.1038/bcj.2011.39 22829077
28. Microarray-based comparative genomic hybridization of cancer targets reveals novel, recurrent genetic aberrations in the myelodysplastic syndromes. Kolquist KA, Schultz RA, Furrow A, Brown TC, Han J-Y, Campbell LJ, Wall M, Slovak ML, Shaffer LG, Ballif BC, Cancer Genet 2011 204 603 628 10.1016/j.cancergen.2011.10.004 22200086
29. Additional genomic aberrations identified by single nucleotide polymorphism array-based karyotyping in an acute myeloid leukemia case with isolated del(20q) abnormality. Hahm C, Mun YC, Seong CM, Chung WS, Huh J, Ann Lab Med 2012 32 445 449 10.3343/alm.2012.32.6.445 23130347
30. SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3. Nowak D, Klaumuenzer M, Hanfstein B, Mossner M, Nolte F, Nowak V, Oblaender J, Hecht A, Hütter G, Ogawa S, Kohlmann A, Haferlach C, Schlegelberger B, Braess J, Seifarth W, Fabarius A, Erben P, Saussele S, Müller MC, Reiter A, Buechner T, Weiss C, Hofmann W-K, Lengfelder E, Genes Chromosomes Cancer 2012 51 756 767 10.1002/gcc.21961 22488577
31. Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment. Yi JH, Huh J, Kim H-J, Kim S-H, Kim SH, Kim KH, Do YR, Mun Y-C, Kim H, Kim MK, Kim H-J, Kim T, Kim DDH, Ann Hematol 2013 92 459 469 10.1007/s00277-012-1635-7 23262795
32. Database of genomic variants. http://dgv.tcat.ca/
33. Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Schaub FX, Jäger R, Looser R, Hao-Shen H, Hermouet S, Girodon F, Tichelli A, Gisslinger H, Kralovics R, Skoda RC, Blood 2009 113 2022 2027 10.1182/blood-2008-07-167056 19047681
34. Clinical significance of genetic aberrations in secondary acute myeloid leukemia. Milosevic JD, Puda A, Malcovati L, Berg T, Hofbauer M, Stukalov A, Klampfl T, Harutyunyan AS, Gisslinger H, Gisslinger B, Burjanivova T, Rumi E, Pietra D, Elena C, Vannucchi AM, Doubek M, Dvorakova D, Robesova B, Wieser R, Koller E, Suvajdzic N, Tomin D, Tosic N, Colinge J, Racil Z, Steurer M, Pavlovic S, Cazzola M, Kralovics R, Am J Hematol 2012 87 1010 1016 10.1002/ajh.23309 22887079